FY2024 EPS Estimates for ABVX Decreased by Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX) – Stock analysts at Leerink Partnrs cut their FY2024 earnings estimates for ABIVAX Société Anonyme in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.08) per share for the year, down from their prior forecast of ($2.93). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

A number of other analysts also recently issued reports on the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday. Finally, JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Trading Up 3.2 %

Shares of ABVX stock opened at $7.06 on Thursday. The firm’s fifty day moving average price is $6.71 and its two-hundred day moving average price is $8.59. ABIVAX Société Anonyme has a 1 year low of $5.50 and a 1 year high of $16.63.

Institutional Trading of ABIVAX Société Anonyme

Hedge funds have recently made changes to their positions in the company. ADAR1 Capital Management LLC boosted its stake in shares of ABIVAX Société Anonyme by 190.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock valued at $11,078,000 after purchasing an additional 991,781 shares during the last quarter. Franklin Resources Inc. boosted its position in ABIVAX Société Anonyme by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after acquiring an additional 141,710 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in ABIVAX Société Anonyme by 45.7% during the 4th quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock worth $10,512,000 after acquiring an additional 450,413 shares during the period. Millennium Management LLC raised its position in shares of ABIVAX Société Anonyme by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock worth $6,816,000 after acquiring an additional 285,542 shares in the last quarter. Finally, Citadel Advisors LLC lifted its stake in shares of ABIVAX Société Anonyme by 83.5% in the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after purchasing an additional 389,247 shares during the period. 47.91% of the stock is owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.